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Abstract 
 
Stroke prevention is the cornerstone of the management of patients with atrial fibrillation (AF). 
Individual stroke risk stratification is generally the first step of deciding whether oral anticoagulation 
(OAC) will benefit patients with AF.  Given that existing approaches to the prediction of ‘high risk’ 
subjects are of limited value, the initial focus should be the identification of ‘low-risk’ patients who 
do not need antithrombotic therapy.  For this, the CHA2DS2-VASc score (congestive heart failure, 
hypertension, age ≥75 [2 points], diabetes mellitus, previous stroke/transient ischemic attack [2 
pints], vascular disease, age 65-74, female sex) performs well in identifying really low-risk patients 
(score of 0 in males or 1 in females), for whom OAC can be omitted.  
The approach to AF management has changed, with the non-vitamin K antagonist oral anticoagulants 
(NOACs) providing relatively better efficacy, safety and convenience compared with the traditional 
vitamin K antagonists (VKAs).  The latter drugs are performing well, if attention is directed towards 
good quality anticoagulation control, as reflected by a time in therapeutic range (TTR) >70%.  
Nevertheless, OAC use remains suboptimal especially in some regions, such as Asia and Africa. 
Long-term adherence and quality of OAC use need to be maintained for better outcomes in patients 
with AF.  
 
 
Keywords: Atrial fibrillation, Stroke, Prevention, Risk, Anticoagulation, Integrate care 
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Introduction 
 
Atrial fibrillation (AF) is the most common arrhythmia, conferring a fivefold increased risk of 
stroke[1]. AF accounts for 15% of all ischemic strokes and 33% of strokes in the elderly[2]. Stroke 
events resulting from AF are more severe, associated with high risks of morbidity and mortality than 
those of non-AF etiologies[3]. Therefore, stroke prevention is an essential part of management for 
patients with AF.  
 
The approach to stroke prevention for AF merits consideration of three steps. First, recognizing those 
patients at low risk of stroke for whom oral anticoagulation (OAC) can be omitted; second, choosing 
the right anticoagulant according to patient clinical profile; and third, optimizing the quality of 
anticoagulation control, especially if VKA (e.g. warfarin) are used, and attention to long-term 
adherence. 
 
Compared to control or placebo, VKA reduces stroke by 64% and all-cause mortality by 26%[4]. In 
patients using VKA, quality of anticoagulation control is important, and a TTR >70% should be 
maintained to improve outcomes[5]. The introduction of the non-vitamin K antagonist anticoagulants 
(NOACs), including factor II inhibitor, dabigatran, factor X inhibitors, rivaroxaban, apixaban and 
edoxaban, has changed the landscape of stroke prevention in AF patients worldwide, offering 
relatively improved efficacy, safety and convenience compared with the traditional VKAs[6-12]. 
Indeed, all NOACs are associated with a reduced risk for intracranial hemorrhage (ICH), even 
compared with well-controlled VKAs[13, 14]. In addition, NOAC-related bleeding events are less 
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severe, especially for ICH[15]. The use of NOACs is associated with better treatment adherence 
compared with VKAs[16].  
 
Nevertheless, OAC use remains suboptimal especially in some regions, such as Asia and Africa. 
Long-term adherence and quality of OAC use need to be maintained for a better outcome in patients 
with AF[17].  Significant barriers to OAC use still exist, and fear of bleeding events is the major 
reason for non-prescription in clinical practice. Indeed, OAC cessation and non-adherence is 
associated with poor outcomes[18, 19]. In general, clinicians have underestimated the benefits and 
overestimated bleeding risks in OAC use. Of note, aspirin does not reduce the risk of stroke in AF 
patients, but increases the risk of ICH, leading to a neutral or negative net clinical benefit (NCB)[20]. 
 
This narrative review aims to provide an overview of the evidence on stroke prevention for patients 
with AF. We provide an evidence-based pathway of stroke prevention in AF, signposting risk 
evaluation, OAC decision-making and anticoagulation quality control, with the aim of providing a 
simple and holistic approach for stroke prevention and integrated care for patients with AF (Figure 1). 
 
 
Stroke risk stratification and oral anticoagulation decision-making 
 
Stroke risk stratification is the first step in managing AF patients. The risk of stroke in AF is not 
homogenous and increases with the presence of more risk factors for stroke. Given that most patients 
with AF are at risk of stroke, initially ruling out those who are ‘low-risk’ would be a more effective 
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way to direct stroke prevention, following which OAC can be offered to all patients with ≥1 non-
gender stroke risk factors[21].  
 
Patients with low risk of stroke are those with the CHA2DS2-VASc score of 0 in males or 1 in 
females[22]. In guidelines, patients with CHA2DS2-VASc score ≥2 in males or ≥3 in females are 
given a strong recommendation for OAC[23], while for patients with a single non-gender stroke risk 
factor (i.e. CHA2DS2-VASc score of 1 in males or 2 in females), stroke risks may vary with a 
particular risk factor. Overall, the use of OAC should still be considered given the positive net 
clinical benefit (NCB) in such ‘medium-risk’ patients[20, 24-31]. In general, the tipping point for 
obtaining an NCB is a stroke threshold of 1.7%/year for VKA, and 0.9% for the NOACs[32]. 
 
As mentioned, for a single risk factor with same points, the stroke risk could be different. For 
example, AF patients at age of 65 and those at 74 have the same assigned 1 point for age, but the 
stroke risks are clearly different. Patients’ stroke risk is continuous, while a score-based cutoff value 
is made arbitrary to facilitate simplicity and clinical practicality. Thus, some individualization is 
needed, for example, for an AF patient at 64 years and borderline hypertension (e.g. 139/80 mmHg) 
or a pre-diabetic stage, the increased stroke risk would best trigger OAC indication.  
 
In the real-world setting, the stroke risk of patients with AF is not static. Increasing age, different 
blood pressure control, status of heart failure and incident risk factors would all contribute to a 
dynamic change in stroke risk. Thus, a patient without an identified stroke risk factor at baseline may 
need OAC during follow-up. Baseline risk assessment, even using the CHA2DS2-VASc score, may 
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not necessarily relate to stroke risk in five or ten years later. For example, Chao et al studied 31,039 
patients from Asia, and found the mean CHA2DS2-VASc score increased from 1.29 at baseline to 
2.31 during follow-up[33]. The change in risk (i.e. ‘delta CHA2DS2-VASc’) had predictivity for 
stroke events compared with baseline or follow-up CHA2DS2-VASc scores[33]. Therefore, regular 
review and reassessment of stroke risk is recommended in recent guidelines given the dynamic 
nature of stroke risk[34].  
 
Age ≥65 is a risk factor for stroke, but this age threshold has been derived from Western populations. 
Nevertheless, Asian populations have relatively lower age threshold for an increased stroke risk[35]. 
In a cohort study from Taiwan (n=186,570), for example, patients could be further stratified into 2 
subgroups with different stroke risk (>50 years of age: 1.78%/year vs. <50 years of age: 
0.53%/year)[35]. Thus, age 50 to 74 years has been proposed with 1 point in the modified CHA2DS2-
VASc score[36].  
 
A recent study using three nationwide registries including 239,671 AF patients demonstrated that sex 
category (i.e. female sex) in the CHA2DS2-VASc score is a risk modifier rather than a risk factor[37]. 
Females exhibit a higher stroke risk with significant interaction with other risk factors, whereby 
females have a higher risk than males at age ≥65 or with ≥1 other risk factors[37]. 
 
Beyond clinical risk stratification with established risk scores 
There are several biomarker-based scoring systems proposed to predict stroke and/or systemic 
embolism (SE) in patients with AF [38-40]. These scoring systems have included biomarkers based 
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on blood tests or cardiac imaging, and have marginally better c-indexes compared with the 
CHA2DS2-VASc score.  Nevertheless, scoring systems which need laboratory tests would reduce the 
convenience of a swift stroke risk evaluation in busy clinical settings, and delayed biomarker reading 
may defer OAC initiation.  Also, significant heterogeneity of these biomarkers between populations 
and laboratory variability may make it difficult to define a cut-off value, especially since many of the 
studies proposing these biomarker-based scores were from highly selected anticoagulated clinical 
trial cohorts. Also, using a baseline biomarker level to predict stroke events years later may be 
unreasonable, given that patients get older and acquire incident risk factors. Second, some 
biomarkers, such as brain natriuretic peptide, are highly dependent on the patient’s clinical situation, 
e.g. infection, water-sodium retention, etc.   
 
Current risk scores do not consider AF subtypes, i.e., paroxysmal AF, persistent AF, permanent AF, 
as prior studies show that stroke risk is dependent on underlying risk factors rather than the 
arrhythmia subtype[21, 41-43]. Nevertheless, persistent AF may contribute higher stroke risk 
compared with paroxysmal AF[44, 45]. Indeed, in the non-anticoagulated AF patients, AF pattern 
was the second strongest predictor after prior stroke or transient ischemic attack (TIA) with an 83% 
and 44% increased risk for permanent and persistent AF compared with paroxysmal AF[45].  
 
Furthermore, subclinical AF (SCAF) is associated with stroke risk in patients with cardiac 
implantable electronic device (CIED). For example, in the Asymptomatic Atrial Fibrillation and 
Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial 
(ASSERT) trial (n=2,580), SCAF duration >24 h was associated with a significant increased risk of 
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subsequent stroke or SE (hazard ratio [HR] 3.24, [1.51-6.95])[46]. A large analysis from the Atrial 
Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-A) and 
Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have 
Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trials suggested a clear 
gradient of increasing risk of stroke/SE from paroxysmal to persistent to permanent AF, whereby the 
annualized ischemic stroke rates were 2.1%, 3.0% and 4.2% respectively, with an HR of 1.83 (1.43-
2.35) for permanent vs. paroxysmal AF and HR of 1.44 (1.05-1.98) for persistent vs. paroxysmal 
AF[45].  However, we are dealing with wide heterogeneity and variability here, as an individual 
patient may have a short paroxysm during one monitoring period, but get a very long period of AF 
(or SCAF) in the next monitoring period. 
 
AF occurring transiently with stress (AFOTS) presents frequently in the setting of acute illness, 
between 4% to 44%[47], and patients with AFOTS have an AF recurrence rate of 42% at 5 years[48]. 
In one study (n=1,409), stroke risk (HR, 1.13 [0.82-1.57]) did not differ between patients with 
AFOTS and those with incident paroxysmal AF[48]. A large retrospective cohort study (n=48,484) 
demonstrated that patients with resolved AF had a high risk of stroke/TIA compared with those 
without AF (relative risk [RR], 1.63 [1.46-1.83])[49]. 
 
 
Left atrial appendage occlusion 
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Evidence on left atrial appendage occlusion (LAAO) in stroke prevention is increasing, and offers an 
alternative to OAC among patients with contraindications for anticoagulation. Evidence for the use 
of LAAO comes from the WATCHMAN Left Atrial Appendage System for Embolic Protection in 
Patients with Atrial Fibrillation (PROTECT-AF) (n=707)[50] and the Prospective Randomized 
Evaluation of the WATCHMAN Left Atrial Appendage Closure Device in Patients with Atrial 
Fibrillation vs. Long-term Warfarin Therapy (PREVAIL) (n=407)[51] trials.  In their meta-
analysis[52], ischemic stroke/SE rate was numerically higher with LAAO (HR, 1.71; p=0.080), but 
LAAO was associated with a lower risk of hemorrhagic stroke (HR, 0.20; p=0.002) and similar 
major bleeding risk (HR, 0.91; p=0.60)[52].  In the PROTECT-AF study, procedural-related adverse 
events at 7 days after the procedure occurred in 8.7% of patients, including pericardial tamponade 
requiring intervention in 4.0%[50]. In the Amulet Global Observational Registry (n=1,088), major 
procedural complications occurred in 3.2% of patients, including pericardial effusion or tamponade 
in 1.2%, vascular complication in 0.9%, periprocedural stroke in 0.2%, and death in 0.2%[53].  
Currently, LAAO has a Grade IIb recommendation in the 2016 ESC guideline, and is limited to 
patients with high risk of bleeding who refuse to take OAC[23]. The performance of LAAO has 
never been compared against the NOACs in large randomized trials, which may provide more 
insights considering the safety advantages of NOACs over VKA, especially for ICH. One network 
meta-analysis indirectly found a trend towards higher rates of ischemic stroke with Watchman 
compared with NOACs (odds ratio [OR], 2.60 [0.60-13.96]) and a non-significant difference in of 
hemorrhagic stroke (OR, 0.44 [0.09-2.14])[54]. In addition, LAAO cannot eliminate the need for 
antithrombotic therapy, including the peri-procedural anticoagulation and long-term antiplatelet 
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therapy, which may defeat the safety profile of LAAO. 
 
Unmet needs in oral anticoagulant use 
 
Current trends 
Despite the well-documented efficacy and safety of OAC, an unmet OAC use remains common 
worldwide[55, 56]. In the last decade, OAC use remains low (approximately 50%) among AF 
patients at high-risk of stroke[57]. Generally, OAC use in Western countries is better than in Asia. 
 
In the EurObservational Research Programme-Atrial Fibrillation (EOPR-AF) registry from Europe in 
2015 (n=10,000), OAC was used in 79.2%[58]. In the Global Registry on Long-Term Oral 
Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry including 
17,162 patients with AF from Europe, 52.4% of the patients received NOAC, 5.7% received 
antiplatelet alone and only 4.1% remained untreated[59]. Similarly, the Antithrombotic Treatment 
Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation (GARFIELD-AF) registry 
involving recently diagnosed AF from 2010 to 2015 (n=39,670) reported an increase in OAC use 
from 57.4% to 71.1%, and a significant increase of NOACs use from 4.2% to 37.0%, while 
antiplatelet monotherapy declined from 30.2% to 16.6%[60]. 
 
In Asia, suboptimal OAC use is more prevalent. For example, in a survey from China, involving 32 
hospitals and 7,977 AF patients demonstrated OAC use of 36.5% among those with a CHA2DS2-
VASc score ≥2 between 2011 to 2014, although this increased from 30.2% to 57.7%[61]. In AF 
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patients from Korea between 2008 and 2015 (n=276,246), OAC use increased from 34.7% to 50.6% 
and NOAC use accounted for 50% of total OAC use, while aspirin use consistently decreased from 
48.2% to 31.5%[62]. 
 
Quality of anticoagulation control 
Effective anticoagulation using VKA requires a TTR ≥65-70%, but the TTR can be influenced by 
multiple factors, where the more common ones have been summarized in the SAMeTT2R2 score (sex, 
age, medical history, treatment of interaction medication, tobacco use, race)
4 
[63]. A patient on VKA 
with a SAMe-TT2R2 score >2 tends to have suboptimal TTR, who may need more frequent 
international normalized ratio (INR) checks, education/counselling on optimizing VKA use or 
switching instead to a NOAC. In general, the patients with AF from Western populations have higher 
TTR when compared with those from other populations. In the PREvention oF thromboembolic 
events-European Registry in Atrial Fibrillation (PREFER IN AF) registry, for example, the mean 
TTR ranged from 70.3% in Spain to 72.5% in the UK and 81.4% in Germany[64, 65]. The mean 
TTR has been reported as higher in Australia (82%) than in Singapore (58%)[66]. In Malaysia, the 
mean TTR was 65.1% in a professional anticoagulation clinic and only 48.3% in general clinics[67]. 
In Thailand, the mean TTR ranged from 40.1% to 62.7% in a cohort study with 433 AF patients[68]. 
In a survey from Saudi Arabia,  the mean TTR was 59%[69]. Also, in a cross-sectional study from 
South Africa, only 48.5% of patients achieved target therapeutic range[70]. In a subanalysis of the 
Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in 
Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial (n=21,105), the mean TTR was also low 
(56%) in East Asia[71]. 
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Off-label reduced dosage of NOACs 
Despite the well-established efficacy and safety of NOACs, in everyday practice, clinicians are often 
more concerned about drug-related bleeding than ischemic stroke/SE, leading to a high rate of 
inappropriate underdosing of NOACs[72]. Barra et al. demonstrated that 57% of patients who were 
treated with a reduced dose of rivaroxaban did not meet the explicit dose reduction criteria in the 
label[73]. In the ORBIT-AF II registry (Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation phase II),  9.4% of patients received a reduced dose of NOACs, which was associated 
with increased cardiovascular hospitalization (HR, 1.26 [1.07-1.50])[74]. In a real-world study 
including 14,845 AF patients from the U.S., among 13,392 patients without renal indication for dose 
reduction, 13.3% received inappropriate reduced dose of NOACs; such underdosing was associated 
with a higher risk of stroke (HR, 4.87 [1.30-18.26]), but a non-significant difference in major 
bleeding [75]. In this study, patients with age ≥80 had highest proportion of underdosing (apixaban 
48.0%, dabigatran 25.7%, rivaroxaban 35.4%)[75]. Although a few studies showed that even low-
dose NOACs had equivalent efficacy and reduced risk of major bleeding (RR, 0.61 [0.40-0.91]) 
compared to warfarin[76], clinicians should not be encouraged to use off-label dosages of NOACs, 
unless the presence of certain criteria justifying dose reduction – the evidence suggests that there is 
little safety advantage but more adverse outcomes result. 
 
 
Reversal of anticoagulant activity in urgent medical conditions 
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Although the bleeding risk is low in NOACs, reversing the anticoagulation activity is important 
when individuals are suffering from serious bleeding, overdosing or require urgent surgery. In 
general, some supportive measures could be conducted, including mechanical/surgical management, 
volume resuscitation, blood transfusion, prothrombic complex concentrates injection, etc. For 
overdosed patients or those who ingested NOACs within 2 to 4 hours, oral activated charcoal may 
attenuate drug absorption. Hemodialysis is also an optional choice for patient taking dabigatran but 
not for those taking FXa inhibitors given the latter drugs are highly protein-bounded[77]. 
 
More important is that specific reversal agents are/coming to available in market, which 
effectiveness and safety in reversing anticoagulation activity. For example, idarucizumab is a specific 
antibody that binds all the dabigatran in plasma within minutes[78]. In the Reversal Effects of 
Idarucizumab on Active Dabigatran (RE-VERSE AD) study, idarucizumab rapidly (less than 10 
minutes), durably, and safely reversed the anticoagulant effect of dabigatran[79].  
 
Andexanet alpha is a recombinant modified human factor Xa decoy protein that has been shown to 
rapidly (within 2-5 minutes) and completely (>90%) reverse the inhibition of factor Xa[80]. The 
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors (ANNEXA) study is 
an ongoing, multicenter, prospective, open-label, single-group study investigating the role of 
andexanet in patients with acute major bleeding[81]. On the basis of descriptive preliminary analysis 
of this study, an initial bolus and subsequent 2-hour infusion of andexanet substantially reduced anti-
factor Xa, with effective hemostasis occurring in 79%[81].  
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Special patient subgroups 
 
OAC use in some subgroups of patients, e.g. those with high bleeding risk, renal dysfunction, recent 
ICH or very elderly patients, can be challenging. Clinicians should fit the right anticoagulants to 
patient’s clinical profile, including those comorbidities such as acute coronary syndrome (ACS), 
concomitant antiplatelet use, peri-AF ablation procedure, cardioversion, chronic kidney disease 
(CKD) and elderly patients[14]. 
 
High bleeding risk 
When initiating OAC, assessment of bleeding risk is necessary, which should be performed at each 
medical contact, considering the dynamic risk profile of AF patients who are often elderly with 
multiple comorbidities. Bleeding assessment can be done using currently available and validated 
bleeding risk scores, such as the HAS-BLE  score (uncontrolled hypertension, abnormal renal/liver 
function, stroke, bleeding history or predisposition, labile International Normalized Ratio [INR], 
elderly, drugs/alcohol concomitantly)
7
. The HAS-BLED score is easy for clinical application with 
similar or better accuracy in predicting major bleeding events compared with other scoring systems 
which may be more complex and less user-friendly [82-85]. 
 
In ‘real-world’ settings, the individual risk of bleeding is not static. Indeed, among the components of 
the HAS-BLED score, there are modifiable risk factors, including uncontrolled hypertension, 
liver/renal function, anemia, labile INR and drugs/alcohol consumption. The changes or management 
of these risk factors would result in a different status of bleeding risk. Indeed, in a ‘real-world’ 
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nationwide AF cohort (n=19,566), follow-up HAS-BLED or ‘delta HAS-BLED score’ was more 
predictive of major bleeding compared with baseline HAS-BLED score[86]. 
 
A high bleeding risk does not eliminate the need for OAC. The HAS-BLED score and other scoring 
systems were designed to draw attention to modifiable bleeding risk factors[87-89].  and to ‘flag up’ 
patients with high bleeding risk, for whom more frequent follow-up, monitoring and education are 
needed[21]. While modifiable bleeding risk factors should be addressed in all patients, relying on 
this alone is an inferior strategy to an established bleeding risk score to assess bleeding risk[87, 90, 
91]. 
 
Very elderly patients 
Evidence for OAC among very elderly patients, such as those over 80 or 90, remains scarce as such 
patients were under-represented in clinical trials. These patients generally comorbid with multiple 
risk factors for stroke and bleeding, thus associating with high risks of both events. A meta-analysis 
(n=8,932) show that the benefit of OAC increases with age, and the harm associated with aspirin 
increases[92]. Such a trend for benefit has also been observed in patients on NOAC[14]. Treatment 
of elderly patients with edoxaban provided a greater absolute reduction in bleeding events over 
warfarin compared to young patients[93]. A recent study from an Asian population, including 11,046 
AF patients >90 years, showed that warfarin was associated with a lower risk of ischemic stroke and 
positive NCB[94]. Furthermore, NOACs were associated with a lower risk of ICH compared with 
the VKA (HR, 0.32[0.10-0.97])[94].  
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Concomitant coronary artery disease (CAD) 
AF commonly coexists with CAD, either as stable CAD or ACS[95]. Thus, combination therapy of 
anticoagulant and antiplatelet agents is commonly used among patients with AF and CAD, which is 
associated with increased risk of bleeding (HR, 1.50 [1.23-1.82])[96]. Among AF patients 
experiencing ACS or undergoing PCI, triple therapy (OAC plus dual antiplatelets) should be used for 
the initial period, followed by OAC plus single antiplatelet drug and after 1 year, OAC alone[97].  
 
The Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy 
with Warfarin in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary 
Intervention (REDUAL PCI) trial (n=2,725) showed lower risk of major or clinically relevant 
nonmajor bleeding with dabigatran plus P2Y12 receptor inhibitor (110mg group: HR, 0.52 [0.42-
0.63] and 150mg group: 0.72 [0.58-0.88] and no significant difference in stroke risk(110mg group: 
HR, 1.30 [0.63-2.67] and 150mg groups: 1.09 [0.42-2.83]), when compared with a warfarin-based 
triple therapy group[98]. In the Prevention of Bleeding in Patients with Atrial Fibrillation 
Undergoing PCI (PIONEER AF-PCI) trial (n=2124), the rivaroxaban group (rivaroxaban 15mg once 
daily plus single antiplatelet group and rivaroxaban 2.5mg twice daily plus dual antiplatelets group) 
had lower risk of bleeding (15mg group: HR, 0.59[0.47-0.76]; 2.5mg group: HR, 0.63[0.50-0.80]), 
compared with triple therapy with warfarin and similar risks of ischemic stroke (15mg group: HR, 
1.07 [0.39-2.96]; 2.5mg group: HR, 1.36 [0.52-3.58])[99]. 
 
Recently, the 2018 Joint European Consensus Document on the Management of Antithrombotic 
Therapy in AF Patients Presenting with ACS and/or Undergoing PCI was published, providing an 
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up-to-date evidence-based guidance on stroke prevention among AF patients with ACS and/or 
undergoing PCI, which is endorsed by HRS, APHRS, LAHRS and CASSA[100]. Other ongoing 
trials will provide new evidence. For example, the Apixaban Versus Warfarin in Patients with AF and 
ACS or PCI study (AUGUSTUS study, NCT02415400) is an open-label, 2×2 factorial, randomized, 
controlled non-inferiority clinical trial to evaluate the safety of apixaban vs. VKA and aspirin vs. 
aspirin placebo in patients with AF and ACS[101]. The Edoxaban Treatments vs. Vitamin K 
Antagonist in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 
(ENTRUST-AF-PCI) study is designed to evaluate the safety and to explore the efficacy of an 
edoxaban-based antithrombotic regimen vs. a VKA-based antithrombotic regimen in subjects with 
AF following PCI with stent placement[102]. 
 
Chronic kidney disease 
The efficacy and safety of anticoagulation are closely related to renal function, especially for the 
NOACs. In patients with CKD (n=48,500), warfarin use was associated with a 30% lower risk of 
stroke /SE and 35% lower risk of death compared with no warfarin use[103]. In subgroup analysis, 
NOACs showed at least similar efficacy and better safety compared with warfarin in patients with 
mild or moderate CKD[14]; however, the excretion of the four NOACs also depends on renal 
function with a degree of renal excretion varying from 27-80%[104]. Of note, all the four NOACs 
randomised trials excluded patients with creatinine clearance (CrCl) <30 mL/min (<25 mL/min for 
apixaban in the ARISTOTLE trial)[6, 105]. Therefore, assessing renal function in AF patients before 
or during taking NOAC is important to choose/modify the dosage of NOAC[106]. In the major 
NOACs trials, the assessment approach of renal function was with the Cockcroft-Gault Equation, 
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which is well-validated and recommended in clinical practice to guide the dose of NOACs in 
CKD[107]. 
 
Currently, evidence on the use of NOAC in patients with CrCl <30 mL/min comes from 
pharmacological modeling. In Europe, reduced dose rivaroxaban, apixaban and edoxaban are 
approved for thromboprophylaxis in patients with CrCl 15-29 mL/min not for patients on dialysis. In 
the USA, the Food and Drug Administration approved the use of reduced-dose of dabigatran (75 mg 
twice daily) in AF patients with CrCl 15-29 mL/min, and in patients with end-stage renal disease on 
dialysis, apixaban (5 mg twice daily)[108]. Given that the CHA2DS2-VASc score is still a useful 
scheme to estimate the risk of stroke in AF patient with ESRD undergoing dialysis[109], a careful 
balancing of risk and benefit of NOACs treatment is possible. 
 
Peri-procedural AF ablation 
Anticoagulation during a peri-procedural period of AF ablation is important given the high inherent 
risk of stroke in this period. The major debate in this field focuses on several points, namely 
uninterrupted OAC use, bridging with heparin, OAC interruption/resumption and switching of OAC 
schemes. Indeed, bridging has been associated with a 4.5-fold increased risk of complications, 
including major pericardial effusion and major vascular events[110].  
 
In the COMPARE (Role of Coumadin in Prevention Thromboembolism in AF Patients Undergoing 
Catheter Ablation) trial (n=1,584), interrupted anticoagulation significantly increased risk of 
thromboembolism (4.94% vs. 0.25%, p<0.001) compared with uninterrupted anticoagulation strategy, 
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while major bleeding complications were non-significantly different (0.76% vs. 0.38%, p>0.05), and 
minor bleeding events were more frequent in the interrupted group (22.0% vs. 4.1%, p<0.001)[111]. 
These results were confirmed by a meta-analysis including 12 studies and 17,434 patients, 
demonstrating that uninterrupted OAC was associated with lower risk of stroke/TIA (0.25% vs. 
1.21%, p=0.003), stroke (0.08% vs. 0.99%, p<0.001), major bleeding (1.44% vs. 2.03%, p=0.02) and 
minor bleeding (5.35% vs. 19.6%; p<0.001) events[112]. Of note, NOACs have better safety and 
similar efficacy among patients receiving AF ablation, compared with the uninterrupted warfarin[10, 
11, 113-115]. 
 
Peri-procedural cardiac electronic devices implantation 
One of the most severe complication after CIED implantation is the pocket hematoma. The Bridge or 
Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL) study, 
included 668 patients experiencing CIED implantation[116]. In this study, clinically significant 
hematoma was seen in 16% of the bridging group as compared to 3.5% of uninterrupted warfarin 
group[116]. Pooled analysis including 11,000 patients also demonstrated a lower risk of pocket 
hematoma in uninterrupted OAC as compared to those receiving bridging heparin therapy[117]. 
Considering the increasing usage of NOAC, the BRUISE-CONTROL-2 trial evaluated whether 
continued versus interrupted NOAC during peri-procedural period would reduce the risk of 
significant pocket hematoma[118].  The trial was stopped early due to futility, and both strategies had 
very low rates of device pocket hematoma. Thus, device surgery could be performed safely without 
interruption of NOACs. 
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For clinical practice, warfarin could be continued with INR controlling between 2.0-3.0. In patients 
taking NOAC, anticoagulation may be discontinued prior to a planned procedure, and the time of 
discontinuation depends on the half-life of respective NOAC and patients’ renal function. For 
patients with normal renal function, NOAC should be discontinued at least 24 hours preoperatively. 
For patients with renal dysfunction, a discontinuation for 48-72 hours seems reasonable. NOAC 
resumption is generally recommended within 24-48 hours after the procedure.  
 
Peri-procedural cardioversion 
The 2016 ESC guideline recommends anticoagulation for ≥3 weeks before elective cardioversion 
and at least 4 weeks thereafter in patients with AF episodes lasting over 48 h or unknown duration, 
regardless of stroke risk profile and types of cardioversion procedure[23]. The NOACs were non-
inferior to warfarin for stroke and bleeding events amongst AF patients undergoing 
cardioversion[119-121].  
 
Recent ischemic stroke 
Patients experiencing recent ischemic stroke events tend to have a high risk of recurrent ischemic 
stroke event and a tendency for hemorrhagic transformation.  A previous meta-analysis demonstrated 
that immediate anticoagulation did not reduce the risk of stroke recurrence but associated with a 
higher risk of hemorrhagic transformation[122]. While early OAC resumption seems to reduce 
recurrent ischemic stroke, there was an increased risk of both intracranial and extracranial 
haemorrhage[123]. 
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As recommended by the 2014 AHA/ASA guidelines, it seems reasonable to initiate OAC within 14 
days for most stroke patients with AF, and delay OAC for more than 14 days in those with high risk 
for hemorrhagic transformation, including large infarct, uncontrolled hypertension, hemorrhagic 
tendency and early hemorrhagic transformation showed by brain imaging[124]. Recently, a simple 
approach was proposed, i.e., the 1-3-6-12 day rule, which suggests that OAC initiation at 1 day after 
TIA; 3 days after a small, nondisabling infarct; 6 days after moderate stroke; and 12 days after a 
large infarct[125]; however, these suggestions are not supported by any trial evidence and are based 
on expert opinion. Given the significantly reduced ICH risk (up to 70%) of NOAC[14], switching 
from traditional VKA to NOAC for patients experiencing recent stroke may provide better safety, 
which merits validation in randomized trials. 
 
Recent intracranial hemorrhage 
Given the lack of high-quality evidence, the most decision-making processes of OAC resumption are 
based on observational studies and empirical expert opinion. A large observation study (n=1,325) 
showed a non-significantly increased risk of ICH recurrence in patients restarted with warfarin 
compared with those without OAC resumption after ICH (HR, 1.31 [0.68-2.50])[126]. This was also 
confirmed by a recent meta-analysis which included 5,306 patients with ICH[127]. In contrast, OAC 
resumption is associated with a 51-66% reduced risk of thromboembolism[126, 127]. 
 
In another large insurance-based study involving 12,917 AF patient with previous ICH, Chao TF et 
al. found that the benefits of warfarin use are dependent on individual stroke risk (i.e. CHA2DS2-
VASc score)[128]. In this study, among patients with a CHA2DS2-VASc score ≥6, the number needed 
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to treat for preventing 1 ischemic stroke was lower than the number needed to ham for producing 1 
ICH with warfarin use (37 vs. 56); however, in patients with a CHA2DS2-VASc score <6, the number 
needed to treat was higher than the number needed to harm (63 vs. 53)[128].  
 
The time of OAC resumption after ICH is an important factor for outcomes and it depends on 
individual. Normally, OAC could be resumed within 2-4 weeks after ICH, but delayed (>4 weeks) 
resumption should be considered for patients with extremely high risk of bleeding. For example, in 
patients with brainstem or cerebellar ICH, the timing could be delayed to at least 8-10 weeks after 
the event[129]. For AF patients with an extremely high CHA2DS2-VASc score (e.g. >4), an early 
OAC resumption seems reasonable after confirming the ICH is resolved.  
 
 
Patient-centered management 
 
Patient-centred approaches may help optimize management amongst patients with AF, with focus on 
patient values and preferences[130, 131]. A shared decision-making process with patients regarding 
OAC use may improve anticoagulation management[132]. More recently, improved education and 
counseling could be reinforced by smart technology, such as apps on smartphones. For example, the 
pilot mAF App trial, which is the first prospective randomized trial of Mobile Health technology in 
patients with AF, showed that integrating clinical decision support, education and patients-involved 
management significantly improved drug adherence[133]. Also, a telemonitoring procedure leads to 
good adherence and could be improved with additional feedback from patients[134].  
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Integrated care 
AF patients are often elderly with multiple comorbidities, and have a high risk of all-cause mortality 
and hospitalization. Indeed, nearly 70% of deaths are caused by cardiovascular disease[135], despite 
high rates of anticoagulation. Most deaths in AF are not related to stroke (which only accounts for 1 
in 10 deaths), while 7 in 10 deaths are cardiovascular.  Thus, a more integrated management strategy 
is needed.  Such ‘integrated care’ in AF has been associated with a lowered risk of death and 
hospitalizations[136].  
 
Integrated care can be simplified into the “Atrial Fibrillation Better care (ABC)” pathway, as follows: 
‘A’ Avoid stroke with Anticoagulation; ‘B’ Better symptom management, involving patient-centred, 
symptom-directed decisions on rate or rhythm control; and ‘C’ Cardiovascular and other comorbidity 
risk management, including attention to lifestyle changes (obesity management, regular exercise, 
avoiding alcohol, etc.)[137] (Figure 1).  Compliance with this ABC pathway approach has been 
shown to reduce mortality and other adverse events in anticoagulated patients with AF[138]. 
 
 
Conclusion 
 
Stroke prevention in patients with AF is the cornerstone of management for this common arrhythmia. 
Current efforts will still focus on the following: (i) Improving the accuracy of identifying patients at 
low risk for thromboembolism; (ii) Exploring more effective and safer approaches to avoid stroke, 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
24 
 
based on a better understanding of the mechanism of stroke events in AF; and (iii) Increasing OAC 
use and patients’ adherence, especially in many regions of the world, such as Asia, Africa and Middle 
East. Stroke prevention is merely one component of an integrated managing approach to AF, and 
attention to symptoms and cardiovascular or comorbidity management should also be emphasized. 
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FIGURE LEGENDS 
Figure 1. The “ABC” pathway and “Birmingham 3-step” for AF management and stroke 
prevention 
 
NOAC=non-vitamin K antagonist anticoagulant; OAC=oral anticoagulant; TTR=time in therapeutic 
range; VKA=vitamin K antagonist. 
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Figure 1 
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Highlights: 
 
(i) Stroke prevention in patients with AF should initially focus on identifying low-risk group for 
which anticoagulation could be omitted;  
(ii) In everyday clinical practice, anticoagulation decisions should be based on - but not limited to - 
the established stroke risk scores; while individualization and attention to patient values and 
preferences is necessary; 
(iii) Unmet needs in anticoagulation use are prevalent, especially among Asian and Africa 
populations; quality control for anticoagulation is important which has impact on outcomes. 
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